Orange Book Warnings Highlight FTC's Drug Price Focus
Seizing yet another arrow in the Biden administration's quiver to combat what it sees as artificially high drug prices, the Federal Trade Commission continues its brigade against so-called junk Orange Book...To view the full article, register now.
Already a subscriber? Click here to view full article